Javascript must be enabled to continue!
HIV- 1: To Splice Or Not To Splice, That Is THE Question
View through CrossRef
HIV-1 transcribes only one kind of transcript – the full length genomic RNA. To make the mRNA transcripts for the accessory proteins Tat and Rev, the genomic RNA must completely splice. The mRNA transcripts for Vif, Vpr, and Env must splice but not completely. Genomic RNA (which also functions as mRNA for the Gag and Gag/Pro/Pol precursor polyproteins) must not splice at all. HIV-1 can tolerate a surprising range in the relative abundance of individual transcript types, and a surprising amount of aberrant and even odd splicing; however, it must not over-splice, which results in the loss of full length genomic RNA and has a dramatic fitness cost. Cells typically do not tolerate unspliced/incompletely spliced transcripts, so HIV-1 has to circumvent this cell policing mechanism to allow some splicing while suppressing most. Splicing is controlled by RNA secondary structure, cis-acting regulatory sequences which bind splicing factors, and the viral protein Rev. There is still much work to be done to clarify the combinatorial effects of these splicing regulators. These control mechanisms represent attractive targets to induce over-splicing as an antiviral strategy. Finally, splicing has been implicated in latency, but to date there is little supporting evidence for such a mechanism. In this review we apply what is known of cellular splicing to understand splicing in HIV-1, and also present data from our newer and more sensitive deep sequencing assays quantifying the different HIV-1 transcript types.
Title: HIV- 1: To Splice Or Not To Splice, That Is THE Question
Description:
HIV-1 transcribes only one kind of transcript – the full length genomic RNA.
To make the mRNA transcripts for the accessory proteins Tat and Rev, the genomic RNA must completely splice.
The mRNA transcripts for Vif, Vpr, and Env must splice but not completely.
Genomic RNA (which also functions as mRNA for the Gag and Gag/Pro/Pol precursor polyproteins) must not splice at all.
HIV-1 can tolerate a surprising range in the relative abundance of individual transcript types, and a surprising amount of aberrant and even odd splicing; however, it must not over-splice, which results in the loss of full length genomic RNA and has a dramatic fitness cost.
Cells typically do not tolerate unspliced/incompletely spliced transcripts, so HIV-1 has to circumvent this cell policing mechanism to allow some splicing while suppressing most.
Splicing is controlled by RNA secondary structure, cis-acting regulatory sequences which bind splicing factors, and the viral protein Rev.
There is still much work to be done to clarify the combinatorial effects of these splicing regulators.
These control mechanisms represent attractive targets to induce over-splicing as an antiviral strategy.
Finally, splicing has been implicated in latency, but to date there is little supporting evidence for such a mechanism.
In this review we apply what is known of cellular splicing to understand splicing in HIV-1, and also present data from our newer and more sensitive deep sequencing assays quantifying the different HIV-1 transcript types.
Related Results
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
OSPHL in collaboration with APHL, will evaluate the performance of the Oxford Nanopore Technology sequencers for HIV genome sequencing using a modified protocol of the ARTIC amplic...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
The strength of the HIV-1 3' splice sites affects Rev function
The strength of the HIV-1 3' splice sites affects Rev function
Abstract
Background
The HIV-1 Rev protein is a key component in the early to late switch in HIV-1 splicing from early intronless (e.g. tat, rev) ...
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Background: HIV rapid diagnosis in The Gambia is mainly done using Determine HIV-1/2 and First Response HIV 1.2.0 or SD Bioline HIV-1/2 3.0 for screening and sero-typing of HIV res...
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Background: The HIV pandemic has attracted unprecedented scale-up in resources to curb its escalation and manage those afflicted. Although evidence from developing countries sugges...
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Background: HIV/AIDS remains a global health problem in Indonesia, with major barriers being misunderstandings, social stigma, and ineffective educational approaches. The level of ...
Abstract 5594: Progression of paraproteinemia in HIV-positive versus HIV-negative patients
Abstract 5594: Progression of paraproteinemia in HIV-positive versus HIV-negative patients
Abstract
BACKGROUND: Paraproteinemias occur in 1 to 3% of people over the age of 50 and progress to hematological malignancies (HM) at the rate of about 1% per year....

